MedTrace Logo

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

NCT03844360 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2025-03-30

No results posted yet for this study

Summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Conditions

  • Hematological Neoplasms

Interventions

DRUG

Bortezomib

bortezomib was administered follow the doctor's advice.

DRUG

Eltrombopag

eltrombopag was administered follow the doctor's advice.

DRUG

Imatinib

imatinib was administered follow the doctor's advice.

DRUG

dasatinib

dasatinib was administered follow the doctor's advice.

DRUG

Pegaspargase

pegaspargase was administered follow the doctor's advice.

DRUG

Anti-Infective Drugs

anti-infective drugs was administered follow the doctor's advice.

DRUG

PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor

pegaspargase was administered follow the doctor's advice.

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    collaborator OTHER

  • Wei Zhao

    lead OTHER

Principal Investigators

  • Wei Zhao, Ph.D · Shandong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Day
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03844360 on ClinicalTrials.gov